Vinpocetine - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Vinpocetine improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia;enhances the transport of glucose to the brain through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca²⁺-dependent phosphodiesterase; increases the levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP). Increases the concentration of adenosine triphosphate (ATP) and the ratio of ATP / AMP in the brain tissues. Increases the exchange of norepinephrine and serotonin of the brain; stimulates the ascending branch of the noradrenergic system. Has antioxidant effect. Improves microcirculation in the brain by reducing aggregation of platelets, reducing blood viscosity, increasing the deformability of erythrocytes. Promotes increased oxygen release by erythrocytes. Increases cerebral blood flow, reduces the resistance of cerebral vessels without significant effect on the parameters of the systemic circulation (blood pressure, minute volume, heart rate, total peripheral resistance). Vinpocetine does not cause the phenomenon of "stealing", primarily increases blood supply in the ischemic areas of the brain, without changing the blood supply of intact areas.

Pharmacokinetics:

When ingestion is rapidly absorbed in the gastrointestinal tract, mainly in the proximal parts of the small intestine. When passing through the wall of the intestine is not exposed to metabolism. The maximum concentration in the blood plasma is achieved 1 hour after ingestion

Easily penetrates through the histohematetic barriers (including blood-brain and placental) in the tissue, breast milk. The maximum concentration in the tissues is noted 2-4 hours after ingestion. Communication with blood plasma proteins - 66%, bioavailability when receiving on an empty stomach - 7%, after meals - about 60%. Clearance (66.7 l / h) exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism.

The half-life in humans is 4.83 ± 1.29 hours. It is excreted by the kidneys and through the intestine in a ratio of 3: 2.

Indications:

Acute (after completion of the course of parenteral administration of vinpocetine, and also in cases when parenteral administration is not shown or impossible) and chronic forms of cerebral circulatory insufficiency (including acute and residual stages of stroke, transient ischemic attacks, encephalopathies, multi-infarct dementia).Vascular diseases of the retina and / or choroid of the eye (due to arteriosclerosis, angiospasm, thrombosis), secondary glaucoma (due to vascular obturation). Ménière's disease.

Contraindications:

Hypersensitivity to the drug components, lactase deficiency, lactose intolerance, fructose, glucose-galactose malabsorption, severe cardiac arrhythmias, ischemic heart disease (severe course), acute stage of hemorrhagic stroke, pregnancy, breast-feeding period, children under 18 years.

Pregnancy and lactation:The use of the drug during pregnancy and breastfeeding is contraindicated. If you need to use the drug during breastfeeding, breastfeeding should be discarded.

Dosing and Administration:

Inside, after eating. Usually the daily dose is 15-30 mg (5-10 mg 3 times a day). The initial daily dose is 15 mg. The maximum daily dose is 30 mg. Therapeuticthe effect develops about a week after the start of the drug. Duration of the course of treatment up to 3 months (treatment course and dosage is determined by the attending physician).

In diseases of the kidneys and liver, the drug is prescribed in the usual dose.

Side effects:

From the cardiovascular system: lability (more often decrease) of arterial pressure, tachycardia, extrasystole, slowing of intraventricular conduction, electrocardiogram change (ST segment depression and Q-T interval elongation), sensation of hot flashes.

From the central nervous system: sleep disturbances (insomnia, increased drowsiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease), increased sweating.

From the digestive system: dryness of the oral mucosa, nausea, heartburn.

From the skin: redness, skin allergic reactions.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, inform the doctor about it.

Overdose:

Treatment: when intoxication is recommended gastric lavage, the reception of activated charcoal and symptomatic treatment.

Interaction:

Increases the risk of hemorrhagic complications against heparin therapy.

Perhaps some strengthening of the hypotensive effect with the simultaneous use of vinpocetine with methyldopa (blood pressure control is necessary).

Special instructions:

In the case of the original interval extension Q-T, as well as with the simultaneous use of Vinpocetine with drugs that extend the interval Q-T, periodic monitoring of the electrocardiogram is necessary.

Effect on the ability to drive transp. cf. and fur:Does not affect the ability to drive vehicles and service moving machinery.

Form release / dosage:

Tablets 5 mg.

Packaging:

For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

For 2, 3 or 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LS-002653

Date of registration:21.03.2012

Expiration Date:Unlimited

The owner of the registration certificate:KIROVSKAYA PHARMACEUTICAL COMPANY, LTD. KIROVSKAYA PHARMACEUTICAL COMPANY, LTD. Russia

Manufacturer: & nbsp

KIROVSKAYA PHARMACEUTICAL COMPANY, LTD. Russia

Information update date: & nbsp17.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)